Application of Physiologically Based Pharmacokinetic Modeling to Characterize the Effects of Age and Obesity on the Disposition of Levetiracetam in the Pediatric Population.

Patricia D Maglalang Jaydeep Sinha Kanecia O Zimmerman Sean McCann Andrea N Edginton Christoph P Hornik Chi D Hornik William J Muller Amira Al-Uzri Marisa Meyer Jia-Yuh Chen Ravinder Anand Eliana M Perrin Daniel Gonzaleznull null

Published in: Clinical pharmacokinetics (2024)

PBPK modeling simulations revealed that the current US FDA-labeled pediatric dosing regimen listed in the prescribing information can produce the required exposure of levetiracetam in these target populations with dose adjustments for children with obesity aged 4 years to younger than 16 years.

Keyphrases

insulin resistance
metabolic syndrome
weight loss
high fat diet induced
type diabetes
weight gain
primary care
young adults
molecular dynamics
emergency department
health information
computed tomography
pet imaging
physical activity
adverse drug
social media
monte carlo
genetic diversity
electronic health record